SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
CDNA

CareDx, Inc. (NASDAQ:CDNA)

US · Delayed Price · Currency is USD
Healthcare · Medical - Diagnostics & Research
$70.00-$1.92 (-2.67%)
 
Market cap
$3.68B
Insider Score
Health Score
Analyst consensus
Listed since
Jul 17, 2014
Website
Market Cap$3.68B+289.8%
Revenue (ttm)$497.40M+38.9%
Net Income$128.63M+111.7%
EPS$2.39+100.6%
Shares Out52.54M
PE Ratio28.11
Forward PE44.75
Dividendn/a
Ex-Dividend Daten/a
Volume781,924
Open$70.56
Previous Close$71.92
Day's Range$69.26 - $72.81
52-Week Range$15.56 - $90.87
Beta2.49
AnalystsBuy
Price Target$80.20(+14.57%)
Earnings DateFeb 23, 2027

About CDNA

CareDx, Inc. is a global innovator specializing in the discovery, development, and commercialization of diagnostic and management tools designed for transplant recipients and their healthcare providers. The company's extensive portfolio features a range of specialized diagnostic solutions for organ monitoring, including: AlloSure Kidney, AlloSure Heart, and AlloSure Lung: Advanced tests employing donor-derived cell-free DNA (dd-cfDNA) technology to assess the health of kidney, heart, and lung transplants, respectively. AlloMap Heart: A gene expression-based solution specifically for heart transplant patients. AlloSeq cfDNA: A broader surveillance tool to measure dd-cfDNA levels in the blood. CareDx also provides cutting-edge human leukocyte antigen (HLA) typing technologies, such as TruSight HLA, an NGS-based high-resolution typing solution; Olerup SSP, which uses sequence-specific primer technology for HLA allele typing; QTYPE for precise HLA typing; and AlloSeq Tx, another high-resolution HLA typing offering. For stem cell transplant recipients, the company offers AlloSeq HCT for chimerism testing. Beyond diagnostics, CareDx develops vital software and digital platforms to streamline transplant patient management. These include Ottr, a dedicated transplant patient management software; XynQAPI, focused on transplant quality tracking and waitlist management; and AlloCare, a mobile application serving as a patient-centric resource for those who have undergone transplantation. The company distributes its products directly to clients, as well as through a network of third-party distributors and sub-distributors. CareDx has forged significant partnerships, including a licensing agreement with Illumina, Inc. for the distribution, development, and commercialization of next-generation sequencing (NGS) products and technologies. Additionally, it collaborates with Cibiltech SAS to commercialize iBox, a software designed for the predictive analysis of kidney allograft loss post-transplantation. Founded in 1998, the company was initially known as XDx, Inc. before rebranding to CareDx, Inc. in March 2014. Its headquarters are located in South San Francisco, California.

Address
8000 Marina Boulevard, Brisbane, CA, 94005, US
Market Cap
3.68 billion
Employees
763
Industrial Classification
Medical - Diagnostics & Research

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$6.81M
Bought
$0

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Analyst consensus

Moderate Buy
2 Buy0 Hold0 SellAvg target $71.00 (+1.4%)

2 firms rating CDNA in the last 3 months, one vote each. Issuer-paid research is not counted.

Financial Health Score
Strong
From CDNA’s reported statements · Q3 2026 (trailing 12 months)

Next catalysts

1 Day
-2.67%
5 Days
-9.42%
1 Month
+1.21%
6 Months
+223.62%
1 Year
+289.76%

$CDNA stock is featured in our Insider Score Rankings, Congress Trading, and Insider Trades datasets.

→ All Stock Lists

Congress Trading

Recent trades of CDNA by members of U.S. Congress

Tom MalinowskiHousePurchase$15.00K – $50.00KMar 2, 2021
Tom MalinowskiHouseSale$1.00K – $15.00KJun 19, 2019
Tom MalinowskiHouseSale$1.00K – $15.00KJun 17, 2019
Tom MalinowskiHousePurchase$1.00K – $15.00KApr 1, 2019
Tom MalinowskiHouseSale$15.00K – $50.00KMar 11, 2019

Recently reported changes in CDNA holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by CDNA's directors and management

Net Shares Purchased by Insiders−90k−45k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

CDNA Estimated quarterly lobbying spending

Source: U.S. Senate LDA

CDNA Revenue by Segment or Geography

CDNA's latest filing doesn't break out revenue by segment.

As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New CDNA patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to CDNA from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in CDNA

VTIVanguard Morningstar Total Stock Market ETF$107.74M
XBIState Street SPDR S&P Biotech ETF$97.40M
IWMiShares Russell 2000 ETF$96.42M
ARKGARK Genomic Revolution ETF$59.97M
VXFVanguard Extended Market ETF$51.23M
IWOiShares Russell 2000 Growth ETF$34.83M

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from CDNA’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
48% of score
0
Analyst Ratings
32% of score
85
News & Sentiment
20% of score
72

News check: Medicare coverage decision removes reimbursement headwind; Q3 performance driven by favorable ruling; analyst target suggests 28% upside potential.

Recent Insider Activity

Buys
0
Sells
20
Buy Value
$0
Distinct Buyers
0

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

FFTYCapForce IBD 50 ETF4.53%
ARKGARK Genomic Revolution ETF3.54%
GNOMGlobal X - Genomics & Biotechnology ETF2.86%
PTHInvesco Dorsey Wright Healthcare Momentum ETF2.54%
GNMXCorgi ETF Trust I - Corgi Genomics & Precision Medicine ETF2.41%
SAWSAAM Sawgrass U.S. Small Cap Quality Growth ETF2.36%
HTECROBO Global Healthcare Technology and Innovation ETF2.29%
HELXFranklin Genomic Advancements ETF2.09%
BOUTCapForce IBD Breakout Opportunities ETF1.94%
BRNYBurney U.S. Factor Rotation ETF1.85%
HYPGolden Eagle Dynamic Hypergrowth ETF1.69%
EKGFirst Trust Nasdaq Lux Digital Health Solutions ETF1.33%

Weight is the stock’s share of each fund’s holdings.